invited to attend the meetings and participate in Board deliberations. Like all Board meetings, the March 18, 2006, meeting was a public meeting and all entities, both large and small, were able to express their views on this issue. Finally, interested persons were invited to submit information on the regulatory and informational impacts of this action on small businesses.

An interim final rule concerning this action was published in the **Federal Register** on December 22, 2006. Copies of the rule were mailed by the Board's staff to all Board members and potato handlers. In addition, the rule was made available through the Internet by USDA and the Office of the Federal Register. The interim final rule provided for a 60-day comment period which ended February 20, 2007. Two comments were received, both of which were in support of the change.

A small business guide on complying with fruit, vegetable, and specialty crop marketing agreements and orders may be viewed at the following Web site: *http://www.ams.usda.gov/fv/moab.html.* Any questions about the compliance guide should be sent to Jay Guerber at the previously mentioned address in the **FOR FURTHER INFORMATION CONTACT** section.

After consideration of all relevant material presented, including the Board's recommendation, and other information, the interim final rule as published in the **Federal Register** (71 FR 76899, December 22, 2006), is adopted, as a final rule, without change.

**List of Subjects in 7 CFR Part 1207**

Advertising, Agricultural research, Imports, Potatoes, Reporting and recordkeeping requirements.

## PART 1207—POTATO RESEARCH AND PROMOTION PLAN

■ Accordingly, the interim final rule amending 7 CFR part 1207 which was published at 71 FR 76899 on December 22, 2006, is adopted as a final rule without change.

Dated: March 29, 2007.

**Lloyd C. Day,**

*Administrator, Agricultural Marketing Service.*

[FR Doc. E7–6274 Filed 4–3–07; 8:45 am]

**BILLING CODE 3410–02–P**

## COMMODITY FUTURES TRADING COMMISSION

### 17 CFR Parts 140 and 145

### Corrections to Regional Office Information

**AGENCY:** Commodity Futures Trading Commission.

**ACTION:** Final rule.

**SUMMARY:** The Commodity Futures Trading Commission (''Commission'') is amending its regulations to delete references to the Minneapolis office, which was closed as of December 31, 2006, and to update the address of the Southwestern regional office.

**DATES:** Effective April 4, 2007.

**FOR FURTHER INFORMATION CONTACT:** Stacy Yochum, Deputy Executive Director, at (202) 418–5157, Office of the Executive Director, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st St., NW., Washington DC 20581; e-mail *syochum@cftc.gov.*

**SUPPLEMENTARY INFORMATION:** Commission Rule 140.2 describes the organization and location of the Commission's regional offices in New York, Chicago, and Kansas City (the Eastern, Central, and Southwestern regional offices). As of December 31, 2006, the Commission closed the Minneapolis sub-office of the Southwestern regional office. In addition, the Kansas City office moved to a new location in September 2004. The Commission is therefore amending Rule 140.2 to delete the reference to the Minneapolis office and to reflect the new address of the Southwestern regional office. There is no change to the states covered by the Southwestern region. The Commission is also replacing the term ''regional director'' with ''regional coordinator'' to reflect the term used by the Commission to describe the head of each regional office.

In addition, the Commission is amending the list of addresses provided in Rule 145.6, which instructs members of the public on where to direct requests for public records, to remove the reference to the Minneapolis office and to update the Kansas City address.

**List of Subjects**

*17 CFR Part 140*

Authority delegations (Government agencies), Organization and functions (Government agencies).

*17 CFR Part 145*

Confidential business information, Freedom of Information.

■ Accordingly, 17 CFR parts 140 and 145 are amended as follows:

## PART 140—ORGANIZATION, FUNCTIONS, AND PROCEDURES OF THE COMMISSION

■ 1. The authority citation for part 140 continues to read as follows:

**Authority:** 7 U.S.C. 2 and 12a.

■ 2. Section 140.2 is amended by revising the section heading, the introductory text, and paragraph (c) to read as follows:

**§ 140.2 Regional Office-Regional Coordinators.**

Each of the Regional offices described herein functions as set forth in this section under the direction of a Regional Coordinator who, as a collateral duty, oversees the administration of the office and represents the Commission in negotiations with employee union officials and in interactions with external parties. Each regional office has delegated authority for the enforcement of the Act and administration of the programs of the Commission in the particular regions.

* * * * *

(c) The Southwestern Regional Office is located at Two Emanuel Cleaver II Blvd., Suite 300, Kansas City, Missouri 64112, and is responsible for enforcement of the Act and administration of the programs of the Commission in the States of Alaska, Arizona, Arkansas, California, Colorado, Hawaii, Idaho, Iowa, Kansas, Louisiana, Minnesota, Missouri, Montana, Nebraska, Nevada, New Mexico, North Dakota, Oklahoma, Oregon, South Dakota, Texas, Utah, Washington, and Wyoming.

## PART 145—COMMISSION RECORDS AND INFORMATION

■ 3. The authority citation for part 145 continues to read as follows:

**Authority:** Pub. L. 99–570, 100 Stat. 3207; Pub. L. 89–554, 80 Stat. 54; Pub. L. 98–502, 88 Stat. 1561–1564 (5 U.S.C. 552); Sec. 101(a), Pub. L. 93–463, 88 Stat. 1389 (5 U.S.C. 4a(j)); unless otherwise noted.

■ 4. Section 145.6 is amended by revising paragraph (a) to read as follows:

**§ 145.6 Commission office to contact for assistance; registration records available.**

(a) Whenever this part directs that a request be directed to the Assistant Secretary of the Commission for FOI, Privacy and Sunshine Acts Compliance, the request shall be made in writing and shall be addressed or otherwise directed to the Office of the Secretariat, Commodity Futures Trading

Commission, Three Lafayette Centre, 1155 21st Street, NW., Washington, DC 20581. Requests for public records directed to a regional office of the Commission pursuant to § 145.2 should be sent to:

Commodity Futures Trading Commission, 140 Broadway, New York, New York 10005, Telephone: (646) 746–9700.

Commodity Futures Trading Commission, 525 West Monroe Street, Suite 1100 North, Chicago, Illinois 60661, Telephone: (312) 596–0700.

Commodity Futures Trading Commission, Two Emanuel Cleaver II Blvd., Suite 300, Kansas City, Missouri 64112, Telephone: (816) 960–7700.

* * * * *

Dated: March 29, 2007.

By the Commission.

**Eileen A. Donovan,**

*Acting Secretary of the Commission.*

[FR Doc. E7–6190 Filed 4–3–07; 8:45 am]

**BILLING CODE 6351–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### 21 CFR Part 520

### Oral Dosage Form New Animal Drugs; Praziquantel and Pyrantel

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an original new animal drug application (NADA) filed by Virbac AH, Inc. The NADA provides for use of chewable tablets containing praziquantel and pyrantel pamoate in dogs and puppies for the treatment and control of various internal parasites.

**DATES:** This rule is effective April 4, 2007.

**FOR FURTHER INFORMATION CONTACT:** Melanie R. Berson, Center for Veterinary Medicine (HFV–110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–7540, e-mail: *melanie.berson@fda.hhs.gov*.

**SUPPLEMENTARY INFORMATION:** Virbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137, filed NADA 141–261 for WORMXPLUS (praziquantel and pyrantel pamoate) Flavored Chewables and VIRBANTEL (praziquantel and pyrantel pamoate) Flavored Chewables that provides for their use in dogs and puppies for the treatment and control of various internal parasites. The NADA is approved as of March 13, 2007, and 21 CFR 520.1871 is amended to reflect the approval.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360b(c)(2)(F)(ii)), this approval qualifies for 3 years of marketing exclusivity beginning March 13, 2007.

FDA has determined under 21 CFR 25.33(d)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of ''rule'' in 5 U.S.C. 804(3)(A) because it is a rule of ''particular applicability.'' Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

**List of Subjects in 21 CFR Part 520**

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

## PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 520 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

■ 2. Amend § 520.1871 as follows:

■ a. Revise the section heading and paragraphs (a) and (b);

■ b. Redesignate paragraph (c) as paragraph (d) and add new paragraph (c); and

■ c. Revise newly redesignated paragraphs (d)(1)(i), (d)(1)(iii), and (d)(2).

The revisions, redesignation, and addition read as follows:

**§ 520.1871 Praziquantel and pyrantel.**

(a) *Specifications*—(1) Each tablet contains 18.2 milligrams (mg) praziquantel and 72.6 mg pyrantel (as pyrantel pamoate).

(2) Each chewable tablet contains 30 mg praziquantel and 30 mg pyrantel pamoate or 114 mg praziquantel and 114 mg pyrantel pamoate.

(b) *Sponsors*. See sponsors in § 510.600(c) for use as in paragraph (d) of this chapter.

(1) See No. 000859 for use of tablet described in paragraph (a)(1) of this section for use as in paragraph (d)(1) of this section.

(2) See No. 051311 for use of tablets described in paragraph (a)(2) of this section for use as in paragraph (d)(2) of this section.

(c) *Special considerations*. See § 500.25 of this chapter.

(d) * * *

(1) * * *

(i) *Dosage*. 1.5 to 1.9 pounds, 1/4 tablet; 2 to 3 pounds, 1/2 tablet; 4 to 8 pounds, 1 tablet; 9 to 12 pounds, 1 1/2 tablets; 13 to 16 pounds, 2 tablets. If reinfection occurs, treatment may be repeated.

* * * * *

(iii) *Limitations*. Not for use in kittens less than 1 month of age or weighing less than 1.5 pounds. May be given directly by mouth or in a small amount of food. Do not withhold food prior to or after treatment. Consult your veterinarian before giving to sick or pregnant animals.

(2) *Dogs*—(i) *Amount*. Administer a minimum dose of 5 mg praziquantel and 5 mg pyrantel pamoate per kilogram body weight (2.27 mg praziquantel and 2.27 mg pyrantel pamoate per pound body weight) according to the dosing tables on labeling.

(ii) *Indications for use*. For the treatment and control of roundworms (*Toxocara canis* and *Toxascaris leonina*), hookworms (*Ancylostoma caninum*, *Ancylostoma braziliense*, and *Uncinaria stenocephala*), and tapeworms (*Dipylidium caninum* and *Taenia pisiformis*) in dogs and puppies.

Dated: March 26, 2007.

**Stephen F. Sundlof,**

*Director, Center for Veterinary Medicine.*

[FR Doc. E7–6181 Filed 4–3–07; 8:45 am]

**BILLING CODE 4160–01–S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### 21 CFR Part 558

### New Animal Drugs for Use in Animal Feeds; Melengestrol and Lasalocid

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.